DEBORAH E.T. SIBLEY, BS, CCRC
*** ****** ******, *******, ** 70068
Cell: 504-***-****

EDUCATION:
Undergraduate: Newcomb College of Tulane University, New Orleans, LA 70118
****-**** ******: BS Biology, 1979 (Minors: Mathematics, Dance)

CERTIFICATIONS:
Clinical Research Coordinator, May 1996, Association of Clinical Research Professionals, USA
Re-certified in 1998, 2000, 2002, 2004, 2006, 2008, 2010, 2012
Certified TaeKwonDo Instructor, June 2002 (annual re-certification), Tiger Rock Martial Arts International

RECOGNITIONS AND HONORS:
Assisted in CRF design with Ortho-McNeil Pharmaceutical, May 1998
Youth Delegate to the Presbyterian Synod of the South, June 1975
Marquis Who’s Who in Science and Engineering, 1993 – 1997
Nominated for the Olympic Torch Relay through the United Way “Be a Community Hero Campaign”, 1996
Nominated for the LSU Medical Center Foundation “Excellence in Research, Education and Patient Care Award”
1996, 1997, 1998 and 2003.
ITA Instructor of the Year for LaPlace, LA 2002.
ITA International Top Ten Ranking - 6th place Free Design 2002, 5th place Free Design 2003, 5th place Sparring &
3rd place Free Design 2004
Advisory Board BioMerieux LRTI protocol, December 2008
Invited Presenter The Medicines Co. PRONTO Investigators Meeting, November 2008
Invited Presenter Cempra Pharmaceuticals Investigator Meeting, August 2010
Inaugural Recipient of the Association of Clinical Research Professionals Annual Outstanding Leadership in
Clinical Research Award as a Clinical Research Coordinator 2011
Invited Presenter Association of Clinical Research Professionals 2013 Global Conference Orlando, FL April 2013
Invited presenter Self Defense Course American Legion Auxiliary Louisiana Department Convention Alexandria,
LA June 2015

PROFESSIONAL SOCIETY MEMBERSHIPS:
Association of Clinical Research Professionals (ACRP) 1995 to present
Study Coordinators’ Advisory Council (SCAC), 1995 to 2000
American College of Emergency Physicians (ACEP), 1996 to 2000
Partners in Policymaking (PIP) – advocacy for the disabled, 1995 to present
Wilderness Medical Society, 1996-1997
American Society for Hypertension (ASH), 1998 to 2000

NON-MEDICAL ACTIVITIES:
2015 to present American Legion Riders Post 383 (Treasurer)
2015 to present American Legion Auxiliary Unit 383 Laplace, LA (Treasurer)
1975 - 1980 Newcombers Jazz Dance Team, Dancer/Director/Choreographer
Newcomb Dance Club, Performer/Choreographer
Lifetime member Girl Scouts of America, Leader/Camp counselor and trainer, Scientific Liason for Southeast Louisiana Council
1982 - 1985 Komenka Ethnic Dance Ensemble, Performer/Choreographer. (performances at 1984 World’s Fair and 1983 Lafayette Cajun Festival)
1996 to 2001 Live Oak Manor Elementary PTO Treasurer
1992 –1996 Cherbonnier Elementary School, Room Mother
1994 – 1996 Greater New Olreans Therapeutic Riding Center (GNOTRC)
1997 – 1998 Jefferson Parish Schools’ Science Fair, Scientific Consultant for Student Projects
1997 to present Tiger Rock Martial Arts International (formerly ITA), (4th Degree Black Belt) Certified Instructor Co-Owner of Sibleys’ TaeKwonDo Plus

PROFESSIONAL MEDICAL EXPERIENCE:
Dec 12-Present Quality Improvement Project Specialist, Pennington Biomedical Research Center, Improving Clinical Outcomes Network (ICON) Network Evaluation Support Team (NEST), Baton Rouge, LA

Aug 02-Dec 12 Clinical Research Coordinator, Department of Medicine, Section of Emergency Medicine, Louisiana State University Health Sciences Center (LSUHSC), New Orleans, LA

Oct 01-Aug 02 8th Grade Science and Language Arts Teacher, Jefferson Parish School Board, Truman Middle School, Harvey, LA

Dec 00-Jul 01 Research Coordinator, Dr. Clinical Research Specialists – Dr. Carolyn Daul (Asthma/Allergy specialist), Metairie, LA

Aug 94-Dec 00 Clinical Research Coordinator, Department of Medicine, Section of Emergency Medicine, Louisiana State University Medical Center (LSUMC), New Orleans, LA

Feb 95-Jun 95 Field Representative, US Department of Commerce, Census Bureau, New Orleans, LA

Sep 90-Dec 93 Research Associate/Chemical Hygiene Officer, Research & Development, Universal Sensors, Metairie, LA

Mar 90-Jun 90 Editor & Temporary Supervisor of Editors, Night Shift, US Department of Commerce, Census Bureau, New Orleans, LA

Oct 87-Mar 89 Medical Research Technician, Veterans Administration Medical Center, Gastroenterology Research Department, New Orleans, LA

Aug 85-Oct 87 Research Associate, Louisiana State University Eye Center (LSUMC), Ophthalmology Research, New Orleans, LA

Dec 83-Aug 85 Geophysical Data-Processimg Exploration Technologist, Amoco Production Corporation, New Orleans, LA

Jan 81-Dec 83 Research Technologist, Veterans Administration Medical Center/Tulane Medical School, Cardiology Research Department, New Orleans, LA

RESEARCH STUDIES:
Studies of Hypertension in dogs and cats and the study of the effect of enkephalins on the cardiopulmonary system, Tulane Medical School
Studies in Corneal Membrane Transport Mechanisms in rabbits and Isolated Corneal chambers, LSU Eye Center
Studies in Human Gastric Acid Secretion, Gastric Acid Blockage in rats and Gastric Acid Peptide Isolation, V.A. Medical Center.
Louisiana Economic Development Council Matching SBIR Grant for Electrode Probes for the Rapid Assay of Seafood Toxins, Universal Sensors
US Army SBIR Phase I – Natural Marine Adhesive Based Electrochemical Immunosensor for In-Field Pathogen Detection, Universal Sensors
NIH SBIR Phase I – Non-Invasive Alcohol Probe, Universal Sensors
US Army SBIR Phase II – Use of Polysaccharides in In-Field Pathogen Detection, Universal Sensors (Principal Investigator Grant Award $850,000))
1994 R.W. Johnson - A Comparison of Safety and Efficacy of IV Levofloxacin vs. IV Ceftriaxone and/or Oral Ceftin in the Treatment of Community Acquired Pneumonia.
1995 Pfizer, Inc. - A Randomized, Multicenter, Investigator-Blind Trial Comparing Intravenous CP 1 16,517 Followed by Oral CP99,219 with Intravenous Ciprofloxacin and AmpiciUin Followed by Oral Ciprofloxacin and Amoxicillin for the Treatment of Community Acquired Pneumonia.
1995 Otsuka America, Inc. Double-Blind Comparative Study of the Efficacy and Safety of Orally Administered OPC-17116 and Clarithromycin in the Treatment of Patients with CommunityAcquired Pneumonia.
1996 Pfizer Inc. A Randomized, Multicenter, Double Blind, Double-Dummy Trial Comparing CP99,219 with Amoxicillin and Optional Erythromycin for the Treatment of Community-Acquired Pneumonia..
1996 Neurex, Inc. A Multicenter, Randomized, Double Blind with Respect to Dose, Evaluation of Intravenous Fenoldopam in Patients with a Hypertensive Emergency. Principal Investigator.
1996 Cambridge NeuroScience. Efficacy and Safe of CERESTAT® (aptiganel HCI) as a
Neuroprotective Following Severe Traumatic Brain Injury.
1996 Pfizer. Intravenous CP 116,517 vs. Zosynfor Treatment of Complicated Skin and Soft Tissue Infections .
1996 Pfizer. Oral CP 99,219 vs. Vantin for Treatment of Uncomplicated Infections Requiring Antibiotic Therapy. Co-Investigator.
1996 Center for Disease Control. A National Emergency Medicine Sentinel Network for Surveillance of Emerging Infections..
1996 R.W. Johnson - A Noncomparative Multicenter Study to Evaluate the Safety and Efficacy of Levofloxacin 500mg Once-Daily in the Treatment of Community Acquired Pneumonia in Adults.
1997 Pfizer, Inc. - A Randomized, Double-Blind, Multicenter, Trial Comparing 10 Days of Oral Therapy with Trovafloxacin CP 99,219 (200mg Once-Daily) and 14 Days of Oral Clarithromycin (500mg, BID) for the Treatment of Acute Sinusitis.
1997 Proctor & Gamble, Inc. A Multi-Center, Double-Blind, Placebo-Controlled Parallel Design Clinical Trial to Assess the Efficacy and Safety of 50mg, 100mg, and 125mg of Azimilide Dihydrochloride for the Prophylactic Treatment of Symptomatic Atrial Fibrillation/Flutter and/or Symptomatic Paroxysmal Supraventricular Tachycardia..
1997 Proctor & Gamble, Inc. A Multi-Center, Open-Label Clinical Trial to Assess the Long-Term Safety of 100mg of Azimilide Dihydrochloride in Patients with Atrial Fibrillation/Flutter and/or Paroxysmal Supraventricular Tachycardia.
1997 Neurex, Inc/Parke-Davis. A Double-Blind, Randomized, Placebo-Controlled Study of CI-1009 in Patients with a Severe Head Injury. Co-Principal Investigator.
1997 Bayer, Inc. A Prospective, Randomized, Comparative Study of Ciprofloxacin and Clarithromycin for the Treatment of Acute Bacterial Exacerbations of Chronic Bronchitis.
1997 Ortho-McNeil Pharmaceutical. Multicenter, Open-Label, Randomized Study to Compare the Safety and Efficacy of Levofloxacin vs. Ceftriaxone Sodium and Erythromycin Followed by Clarithromycin and Amoxicillin/Clavulanate in the Treatment of Serious Community-Acquired Pneumonia in Adults.
1997 ViroPharma, Inc. A Double-Blind, Placebo-Controlled Trial of VP63843 in the Treatment of Enteroviral Meningitis in Adolescents and Adults.
1997 Searle, Inc. Clinical Protocol for Dose Ranging Study of Eplerenone vs. Placebo in Patients with Symptomatic Heart Failure.
1998HMR. A Double-Blind, Multicenter, Randomized, Active Controlled, two-arm, Parallel Group, Comparative study of the Efficacy and Safety of Oral HMR 3647 vs Oral Clarythromycin in the Treatment of CAP in Adults.
1998Merck. A prospective, Multicenter, Double Blind, Randomized, Comparative Study to Evaluate the
Safety, Tolerability and Efficacy of MK-0826 versus Ceftriaxone Sodium in the Treatment of
CAP in Adults..
1998 ViroPharma, Inc. A Double-Blind, Placebo-Controlled Trial of Pleconaril in the Treatment of Enteroviral Meningitis in Adolescents and Adults Principal Investigator.
1999Innovex, Inc. A Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Efficacy Based
on the Time to Treatment of Influenza Infection with the Neuraminidase Inhibitor Ro64-0796.
1999 Integrated Infusion Services. Tetanus Immunity and Wound Prophylaxis Among At-Risk Emergency Department Patients (COWS). Principal Investigator.
1999 Abbott Laboratories. Comparison of the Safety and Efficacy of Clarithromycin IR (250 mg BID) to Levofloxacin (500 mg QD) for the Treatment of Community-Acquired Pneumonia.
1999HMR. An Open-Label, Multicenter, Multinational Uncontrolled Study of the Efficacy and Safety of Oral HMR3647 (800 mg Once Daily) Given for 7 Days in the Treatment of Community-Acquired Pneumonia in Adults. 20 subjects. HMR 3647/3010..
2000SmithKline Beecham
An open, non-comparative, multicenter study to assess the efficacy and safety of oral augemntin SR 2000 mg /125 mg twice daily for 7 days for the treatment of bacterial community acquired pneumonia in adults. BRL-025000/546
2000 SmithKline Beecham
An open, non-comparative, multicenter study to assess the efficacy and safety of oral augemntin SR 2000 mg /125 mg twice daily for 7 days for the treatment of bacterial community acquired pneumonia in adults. BRL-025000/547
2000SmithKline Beecham
A randomized, double-blind, double-dummy, multicenter, parallel group study to assess the effectiveness and health economic impact of oral Factive (gemiflloxacin), 320mg once daily for 5 days versus oral clarithromycin 500mg twice daily for 7 days for the treatment of acute exacerbation of chronic bronchitis (AECB) . SB – 265805/112.
2000 Alexion/Procter and Gamble
Comply: complement inhibition in myocardial infarction treated with thrombolytics. A randomized, double-blind, placebo-controlled study of two intravenous dosing regimen of H5g1.1-scFb in patients with acute myocardial infarction undergoing thrombolytic reperfusion therapy. Comply : 1999052
2000 Aventis
HMR 3647. An Open-Label, Multicenter, Multinational Uncontrolled Study of the Efficacy and Safety of 7 Days of Oral telithromycin (HMR3647 - 800 mg Once Daily) in the Treatment of Community-Acquired Pneumonia Due to Streptococcus pneumoniae in Adolescent and Adults. Protocol No.: HMR 3647/3012.
2001 Ortho McNeil Pharmaceuticals. Multicenter, double blind, randomized study to compare the safety and efficacy of levofloxacin 750 mg once daily for five days vs levofloxacin 500 mg once daily for 10 days in the treatment of mild to severe community-acquired pneumonia in adults. Protocol CAPSS 150.
2001 Ortho McNeil Pharmaceuticals Multicenter, Open Label, Non-Comparative Study to Evaluate the Safety and Efficacy of Levofloxacin 750 mg once a day for 5 days in the Treatment of Mild To Severe Community-Acquired Pneumonia in Adults. Protocol CAPSS-171.
2001Bristol-Myers Squibb. An Open Label, Non-Comparative, Multi-National Study of BMS-284756 in the Treatment of Community Acquired Pneumonia Caused by Penicillin Resistant Streptococcus pneumoniae. Protocol No.: AI464-073.
2002 Aventis Pharmaceuticals. Insulin glargine [rDNA origin] injection (Lantus ) vs. pioglitazone (Actos ) as Add-on Therapy in patients failing Monotherapy with sulfonylurea or metformin (Glucophage ): A randomized, open, parallel study. Protocol No.: HOE901/4020.
2003 Bayer Corporation, A Study of Avelox for Treatment of Elderly Patients with Community Acquired Pneumonia. (The SAFE CAP Study). Protocol 10872. .
2003 Aventis Pharmaceuticals, An Observational, Non-Interventional, Retrospective, International Study to Investigate Factors Responsible for Hospitalization, and Subsequent Outcomes, of Pateints with Community Acquired Pneumonia (CAP) Protocol No.: HMR3647A/9003.
2003 MARC-14 Fourteenth Multicenter Airway Research Collaboration.
2003 Ortho-McNeil Pharmaceuticals. Comparison of the Efficacy and Safety of Tramadol HCl/ Acetaminophen vs Hyrocodone Bitartrate/Acetaminophen versus Placebo in Subjects with Acute Musculoskeletal Pain. Protocol CAPSS-216.
2003 Theravance, Inc. Phase 2, Randomized, Double-Blind, Multinational Trial of Intravenous ARBELIC versus Standard Therapy for Treatment of Complicated Gram-Positive Skin and Skin Structure Infections. .Protocol No.: I6424-202a.
2004 Pfizer, Inc. A Multicenter, Randomised, Double-Blind, Double-Dummy Comparative trial of Azithromycin SR Vs Clarithromycin Extended Release for the Treatment of Mild to Moderate Community-Acquired Pneumonia in Adults. Protocol A0661075. $2,782.16
2005 GlaxoSmithKline..Studies 030A and 030B: Two Identical Double-Blind, Double-Dummy, Multicenter, Comparative Phase III Studies of the Safety and Efficacy of Topical 1% SB-275833, Applied Twice Daily, versus Oral Cephalexin, 500 mg in Adults, or 12,5 mg/kg (250 mg/5ml) in Children Twice Daily, in the Treatment of Uncomplicated Secondarily Infected Traumatic Lesions. Protocol SB-275833/030 $27,654.70 .
2004 Theravance, Inc. FAST 2, Randomized, Double-Blind, Multinational Trial of Intravenous Telavancin versus Standard Therapy for Treatment of Complicated Gram-Positive Skin and Skin Structure Infections. .Protocol No.: I6424-202b. $149,935.00 (w/202a) .
2004 Theravance, Inc. ATLAS II, A Phase 3, Randomized, Double-Blind, Multinational Trial of Intravenous Telavancin vs Vancomycin for Treatment of Complicated Gram-Positive Skin and Skin Structure Infections Due to Methicillin-Resistant Staphylococcus aureus. .Protocol 0018
.2004 Aventis Pharmaceuticals. A Randomized, Double-Blind, Parallel-Group, Multicenter Study to Compare Clinical Health outcomes of Telithromycin vs Azithromycin in Outpatients with Community- Acquired Lower Respiratory Tract Infections (KEYS).
2004 Ortho-McNeil Pharmaceuticals. A Multicenter, Double-Blind, Randomized Study to Compare the Efficacy and Safety of Levofloxacin 750 mg Once Daily for Five Days vs Ciprofloxacin Twice Daily for Ten Days in the Treatment of Complicated Urinary Tract Infection or Acute Pyelonephritis. Protocol CAPSS-349.
2004 Merck & Co, Inc. A Multicenter, Randomized, Double-Blind Study Comparing the Clinical Effects of Intravenous Montelukast with Placebo in Patients with Acute Asthma. Protocol 288-00
2004 Hoffman-La Roche, Inc. A Phase II, Prospective, Randomized, Double-Blind, Active-Controlled, Parallel- Group, Multicenter “Proof of Concept” Trial in Adult Patients with Community-Acquired Pneumonia Requiring Hospitalization Without Evidence of Legionella. Protocol WI18273.
2004 Scios, Inc. ADHERE Acute Decompensated Heart Failure National Registry: Focused on Improving the Continuum of Care (Dr. J. Moises PI)
2004 Agency for Healthcare Research and Quality. Harvard Emergency Department Safety Study. (Dr. L Mills)
2005 Scios Prospective Randomized Outcomes Study of Acutely Decompensated CHF Treated Initially in Outpatients with Natrecor®, THE PROACTION TRIAL. Follow-up Amendment Protocol No: 704.301.
2006 GlaxoSmithKline. A 16-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose-Ranging Study to Evaluate the Efficacy, Safety, and Tolerability of Multiple Doses and Multiple Treatment Regimens of GSK716155, with Byetta as an Open-Label Active Reference, in Subjects with Type 2 Diabetes Mellitus. Protocol GLP110125.
2007 The Medicines Company. Evaluation of the Effect of Ultrashort-Acting Clevidipine in the Treatment of Patients with Severe Hypertension (VELOCITY). Protocol TMC-CLV-06-02.
2007 Targanta Therapeutics Corp. Nuvocid™ (oritavancin) at Single or Infrequent Doses for the Treatment of Complicated Skin and Skin Structure Infections (SIMPLIFI). Protocol TAR-ORI-SD001
.
2008 University of Massachusetts Medical School. STAT (Studying the Treatment of Acute Hypertension).
2009 Molecular Insights Pharmaceuticals. Open-label, Phase 2 Study of the Safety and Efficacy of β-Methyl-P- [123I]-iodophenyl-pentadecanoic acid (Iodofiltic acid I 123) for Identification of Ischemic Myocardium Using Single Photon Emission Computed Tomography (SPECT) in Adults with Symptoms Consistent with Acute Coronary Syndrome (ACS). Protocol MIP-BP23.
2008 Replidyne, Inc. Prospective, Randomized, Double-blind Trial to Evaluate the Efficacy and Safety of Faropenem Medoxomil 600mg PO, BID for 5 days versus Placebo in the Treatment of Acute Exacerbation of Chronic Bronchitis. Protocol REP-FAR-005. .
2008 Replidyne, Inc. Prospective, Randomized, Double-blind Trial to Evaluate the Efficacy and Safety of Faropenem Medoxomil 600mg PO, BID for 10 Days Versus Levofloxacin in the Treatment of Community Acquired Pneumonia. Protocol REP-FAR-011
2008 Wyeth Pharmaceutical, Inc. A Phase 3, Open- Label, Single Arm Trial, Evaluating the Safety, Tolerability and Reactogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Ambulatory Elderly Adults Aged 68 Years and Older Who Received 1 or More Doses of 23-valent Pneumococcal Polysaccharide Vaccine at Least -3 Years Before Study Enrollment. Protocol 6115A1-3000
2008 Ortho-McNeil Janssen, Inc. A prospective, multi-center, observational study involving patients hospitalized with complicated skin and soft tissue infections (cSSTI) for IV antibiotic therapy. Protocol CEFT-SSK- 4001.
2008 The Medicines Company. PRONTO: A Safety and Efficacy Study of Blood Pressure Control in Acute Heart
Failure- A Pilot Study. Protocol No.: TMC-CLV-08-0.
2008 GlaxoSmithKline, Inc. A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus aureus. Protocol No.: TOC110978
2008 Paratek Pharmaceuticals, Inc. to Compare the Safety and Efficacy of PTK 0796 with Linezolid in the Treatment of Adults with Complicated Skin and Skin Structure Infection. Protocol No.: PTK 0796-CSSI-0804..

2010 Cempra Pharmaceuticals Inc. A Randomized Double-blind, Multicenter Study to Evaluate the Efficacy and Safety of Oral CEM-101 Compared to Oral Levofloxacin in the Treatment of Patients with Community Acquired Bacterial Pneumonia. Protocol No.: CE01-200
2010 Nabriva Therapeutics, Inc. A Phase 2, multi-center, randomized, double-blind study comparing the safety and efficacy of two doses of BC-3781 versus vancomycin in patients with acute bacterial skin and skin structure infections. Protocol NoNAB-BC-3781-2001.

2011 The Medicines Company/PPD. A Multicenter, Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of Single-Dose IV Oritavancin versus IV Vancomycin for the Treatment of Patients with Acute Bacterial Skin and Skin Structure Infection Study (SOLO I) Protocol No.: TMC-ORI-10-01 Study Completed November 2012.
Study closed June 2012 We are members of the EMERGEncy IDNet group, subsidized partially by the CDC, to collect epidemiologic data gathering to tract specific emerging infectious diseases: .

2012 Otsuka Pharmaceuticals (CADENCE) A Multi-center, Parallel-group, Double-blind, Placebo-controlled, Randomized, Ascending Dose Trial to Determine the Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous Infusions of OPC-108459 Administered to Subjects With Paroxysmal and Persistent Atrial Fibrillation (PI – LeLorier)

2012 Utility of the 15-lead ECG in predicting response to cardiac resynchronization therapy. (PI – LeLorier)

2012 Duke Clinical Research Institute- DCRI Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation (CABANA) Trial (PI – LeLorier)

2012 Brigham and Women’s Hospital PRE-DETERMINE: Biologic Markers and Sudden Cardiac Death Study [awaiting contract] (PI – Ahmed)

2012 University of Rochester Late Sodium Current Blockade in High-Risk ICD Patients Ranolazine ICD Trial (RAID) [awaiting contract] (PI – LeLorier)

2012 Boeringer Ingelheim GLORIA - AF: Global Registry on Long-Term Oral Anti-thrombotic TReatment In PAtients with Atrial Fib (PI – Ahmed)

2012 Duke Clinical Research Institue –DCRI A randomized, double-blind, parallel group, multicenter phase IIIb study to compare ticagrelor with clopidogrel treatment on the risk of cardiovascular death, myocardial infarction and ischaemic stroke in patients with established Peripheral Artery Disease (EUCLID – Examining Use of tiCagreLor In paD) (PI – Ali)

2012 St Jude Medical Left Atrial Pressure Monitoring to Optimize Heart Failure Therapy Study (LAPTOP-HF) (PI – Smart)

2012 Paragon Biomedical A Pivotal Trial to Establish the Efficacy and Long-term Safety of the Parachute Implant System (PARACHUTE IV) (PI – Ali)

OTHER RESEARCH INTERESTS:
Aggressive ED Management of DKA (Prospective Study). Study in progress.
Aggressive Management of Hypertension in the ED (Prospective Study). Study in progress.
Management of Hyperglycemia in the ED (Prospective Study). Study in progress.
Hyponatremia in Community Acquired Pneumonia
Antibiotic Resistance in Streptococcal Pneumoniae
Co-existence of Typical and Atypical Pathogens in Community Acquired Pneumonia
Recurrence of Skin and Skin Tissue Infections

BIBLIOGRAPHY OF PUBLICATIONS AND PATENTS:
U.S. Army and Universal Sensors, Inc. Patent pending. Use of Natural Marine Adhesives in In-Field Pathogen Detection, 1992

Sibley, D.E.T., Ramsay, G., Lubrano, G.J. And Guilbault, G.G. (1993) Stability and Reusability of Enzyme-linked Immunosorbent Assay (ELISA) Plates, Analytical Letters 26(8), p 1623-1634.

Sibley, D.E.T., Lubrano, G.J. and Guibault, G.G. (1993) Enhancement Effect of Storage Buffer on Regeneration of Immunosorbent Surfaces. Biotechniques (1), January 1994, p 63-64.

Carter, R.M., Poli, M.A., Pesavento, M. Sibley, D.E.T., Lubrano, G.J. and Guilbault, G.G. (1993) Immunoelectrochemical biosensors for detection of Saxitoxin and Brevetoxin. Immunomethods, 3, p128-133.

Guilbault, G.G., Sibley, D.E.T., Carter, R.M. and Lubrano, G.J. (1993) Biosensors for toxins and bacteria in Immobilized Biological Compounds for Detection, Medical, Food and Environmental Analysis. G.G. Guilbault and M. Mascini, eds. Kluwer Academic Publishers, Netherlands, October 1993, p377-385.

Dunbar, LM, Martin, DH, Giddens, J and Sibley, DET, The Bacterial Pathogens of Community Acquired
Pneumonia: Coexistence of Typicals and Atypicals. abstract - Acad. Emergency Medicine, March/April 1995.

Dunbar, L, M,. Jubelin, B.C,. and Sibley, D. Co-existence of Pathogens in Community Acquired Pneumonia (CAP). 40th Annual ICAAC Conference abstract, Toronto, Ont., Canada, September, 2000.

Dunbar, L, Talan, D and Sibley, D for the EMERGEncy IDnet Investigators. Antimicrobial Resistance of Streptococcus pneumoniae Recovered From Patients with Lower Respiratory Tract Infections in the United States During 1997-2000. J Manuscript in preparation

Sibley, D, Dunbar, L, Hunt, J, Tuckler, V, LeGros, T, Marr, A, Ramirez, J, Edler, R, Shateri-Mirabadi, A, Thompson, H, Barriere, S, and Kitt, M. Recurrent Infection Rates in Patients Treated with Telavancin vs. Vancomycin for Complicated Skin and Soft Tissue Infections – Bactericidal Aspect of Telavancin. Manuscript in preparation.

Dunbar, L, Dancour, E., Sibley, D., and Dancour, E. To Admit or Discharge Congestive Heart Failure Patients: Use of a Severity of Illness Index. Manuscript in preparation.

ABSTRACTS AND PRESENTATIONS:
Ramsay, G., Sibley, D.E.T., Lubarano, G.J. and Guilbault, G.G. (1991) Rapid detection of seafood toxins by electrochemical immunoassay. Proc. Pittsburgh Conference, Chicago, IL., 1991

Annual Review of US Army Phase I SBIR grant for Natural Marine Adhesive-Based Electrochemical Immunosensor for In-Field Pathogen Detection, Ft. Detrick, MD December 1991.

Small Business Innovative Research (SBIR) Funding Review of Phase II Manufacture of Instrumentation before the Joint Houses of Congress, Washington, DC, March 1992.

Carter, R.M., Sibley, D.E.T., Poli, M.A. and Lubrano, G.J. (1993) ELISA and immunoelectrochemical detection of the marine toxins: Brevetoxin and Saxitoxin. IBEX 93, San Francisco, CA

Dunbar, L.M., Martin, D.H., Giddens, J. and Sibley, D.E.T. (1995) The Bacterial pathogens of Community acquired pneumonia: Coexistence of typicals and atypicals. Academic Emergency Medicine, March/April 1995.

SAEM Annual Meeting, San Antonio, TX, May 1995. Poster Title: The Bacterial Pathogens of Community Acquired Pneumonia Coexistence of Typicals and Atypicals.

Dunbar, LM, Zaheri, K, Thompson, H, Gonzaba, WT, DeSoto, D. and Sibley, DET. Aggressive ED Management of DKA: Impact on Disposition and Outcome. LSU Dept of Medicine Research Day, January 1997.

Dunbar, LM, Zaheri, K, Thompson, H, Gonzaba, WT, DeSoto, D. and Sibley, DET. Aggressive ED Management of DKA: Impact on Disposition and Outcome. AFCR/Southern Societies Section, February 5, 1997.

Dunbar, LM, Marque, M, Sibley, DET, Thompson, H and Davidowitz, S. Analysis of Blood Pressure Prior to Intervention in Hypertensive Emergencies and Urgencies. ACEP Research Forum, San Francisco, CA, Oct 1997.

Roberts, J, Dunbar, LM, Mazzola, R, Anand, P and Sibley, DET. Serious Childhood Anemia – A Continuing Public Health Problem. ACEP Research Forum, San Francisco, CA. Oct 1997.

Dunbar, LM, et al, ED Management of Hypertensive Emergencies with Fenoldopam, SAEM Annual Meeting, Chicago, IL, 1998.

Dunbar, LM, et al, ED Management of Hypertensive Emergencies with Fenoldopam, SAEM Regional Meeting, New Orleans, LA, 1998.

Dunbar, LM, Jubelin, BCL and Sibley, DET, Co-Existence of Pathogens in Community Acquired Pneumonia (CAP), ICAAC 2000.

Jubelin, B, Hendifar, A, Sibley, D, and Dunbar, L, Hyponatremia in Community Acquired Pneumonia: Is It Truly a Marker for Legionella?, ACEP Research Forum, Las Vegas, NV, October 2000.

Dunbar, L, Jubelin, B, Gohil, R, and Sibley, D, Aggressive Management of Diabetic Ketoacidosis: Time Course for Correction of Metabolic Abnormalities, ACEP Research Forum, Seattle, WA, October 2002.

Dunbar, L, Sibley, D, Waldren, A, and the EMERGEncy Idnet Study Group, Pneumococcal Resistance to Penicillin in Community Acquired Pneumonia, Regional SAEM meeting, Jacksonville, FL, April 2003

Dunbar, L, Talan, D, Sibley, D, and the EMERGEncy Idnet Research Study Group. Antimicrobial Resistance of Streptococcus pneumoniae Recovered From Patients With Lower Respiratory Tract Infections in the United States During 1997-2000, 2nd Mediterranean Emergency Medicine Congress, Barcelona, Spain, September 17, 2003.

Stryjewski, M, O'Riordan, W, Dunbar, L, Lau, W, Pien, F, Fowler, V, Vallee, M, Chu, V, Sibley, D, Barriere, S, Kitt, M, Corey, G, . Telavancin (TLV) vs Standard Therapy (ST) for Treatment of Complicated Gram-Positive Skin and Soft Tissue Infections (cSSTI), 3rd Mediterranean Emergency Medicine Congress, Nice France, September 1-5, 2005.

Dunbar, L, Sibley, D, et al. Recurrence of Skin Infections in Patients Treated with Telavancin vs. Vancomycin for Complicated Skin and Soft Tissue Infections, 4th Mediterranean Emergency Medicine Congress (oral presentation), Sorrento, Italy, September 17, 2007.

Dunbar, L, Ramirez, J, et al. Associations of Clinical and Laboratory Variables in Patients with Community Acquired Pneumonia (CAP), 4th Mediterranean Emergency Medicine Congress (poster presentation), Sorrento, Italy, September 17, 2007.

Dunbar, L, Sibley, D, et al. Recurrence of Skin Infections in Patients Treated withTelavancin versus Vancomycin for Complicated Skin and Soft Tissue Infections in a New Orleans Emergency Department, 42nd ASHP Midyear Clinical Meeting & Exhibition, Las Vegas, NV, December 3, 2007.

Dunbar, L, Sibley, D., et. al. Recurrence of skin infections in patients treated with telavancin versus vancomycin for complicated skin and soft tissue infections in a New Orleans emergency department, 28th International Symposium on Intensive Care and Emergency Medicine, Brussels, Belgium, March 19, 2008.

Sibley, D, Couk, J, Aiken, J, VanMeter, K, Fontenot, C, DeBlieux, P, Moises, J, Agnelly, L, Bryant-Penland, J, Dunbar, L. Impact of Hurricane Katrina on Healthcare Delivery in New Orleans, American College of Emergency Physicians Scientific Assembly and Research Forum, Chicago, IL, October 28, 2008.
Contact this candidate